📄 What This Document Is 📰

This document is an 8-K filing—a major SEC filing—combined with a press release, announcing Philip Morris International’s (PMI) financial results for the first quarter of 2026. 👉 Readers should understand this is a detailed snapshot of the company's performance, covering revenue, profit, and guidance for the rest of the year. It details how PMI is navigating a complex, evolving industry while betting heavily on its smoke-free portfolio.

🏢 What The Company Does 🏭

In simple terms, PMI is a massive global consumer goods company that aims to deliver a "smoke-free future." While its current product line still includes cigarettes and combustibles, the company is aggressively evolving its portfolio to include modern, innovative alternatives outside of traditional tobacco and nicotine.

• Products: The core portfolio includes traditional cigarettes and smoke-free products, such as heat-not-burn (HTU), nicotine pouches (like ZYN), and electronic vapor products (e-vapor).
• Market Reach: Their smoke-free products are currently available for sale in over 105 markets.
• Long-Term Goal: PMI has dedicated significant investment since 2008 ($16 billion+) toward developing and commercializing smoke-free products for adults who would otherwise continue smoking, with the ultimate goal of ending the sale of cigarettes.

💰 Financial Highlights for Q1 2026 📈

The overall financial results show a mix of impressive growth in their smoke-free segment, but also headwinds in the U.S. market. The overall revenues were up compared to the previous year, largely fueled by pricing strength and international smoke-free momentum.

• Total Net Revenues: Increased by 9.1% (or 2.7% organically) to $10.1 billion.
  • Why it matters: This shows solid global top-line growth, but the low organic growth rate (2.7%) suggests that much of the revenue increase was due to price changes rather than simply selling more products.
• Operating Income (Reported): Increased by 9.8% (or 0.9% organically), reaching $3.9 billion.
  • Why it matters: While operating income grew, the slow organic growth (0.9%) suggests that increased costs or operating inefficiencies are tempering the profitability growth.
• Diluted EPS (Earnings Per Share): The Adjusted Diluted EPS grew by 16.0% to $1.96, which is a strong indicator of underlying profitability. However, the Reported Diluted EPS declined by 9.3% to $1.56, due specifically to a non-cash fair value adjustment related to their minority shareholding in India.

🚭 International Smoke-Free Segment Growth 💨

This is the engine driving PMI's performance. The International Smoke-Free segment saw massive growth, significantly outperforming the other parts of the business. This growth is driven by multiple product lines, most notably IQOS.

• Revenue Performance: Net revenues surged by 24.7% (15.8% organically), reaching $3.8 billion.
  • Why it matters: This segment is key to PMI’s future strategy. The high organic growth rate demonstrates that the shift of consumer behavior toward non-traditional products is working in PMI's favor.
• IQOS Dominance: The IQOS heat-not-burn product continues to be the primary growth catalyst. In several key markets, IQOS surpassed Marlboro and achieved a significant market share gain of 1.7 percentage points (pp), reaching 10.9% of combined cigarette and HTU industry volumes.
• Regional Wins:
  • Europe: IQOS adjusted market share grew by 1.1pp to 12.6%. This strong performance occurred despite challenges like ongoing disruptions in Ukraine and the initial implementation of the characterizing flavor ban in Poland.
  • Global Scale: Outside of Europe and Japan, the adjusted market volume grew by an impressive 19.4%.
• Other Products:
  • E-vapor (VEEV): This segment is showing continued profitable growth. VEEV now shares the #1 closed pod market position in Europe, with robust growth in Germany, France, and Italy.
  • Oral SFP (ZYN): While the overall shipment volume decreased by 5.1% (due to snus declines in the Nordics), the business is expanding with ZYN now available in 58 markets, focusing on high-appeal 1.5mg variants.

🚬 International Combustibles Segment Performance 🌿

This segment showed mixed results. While net revenues increased by 6.8%, the growth was minimal on an organic basis (only 1.0%), and shipment volumes actually declined by 5.1%.

• Pricing Strength: The revenue increase was primarily driven by strong pricing, which grew by 8.5%.
• Market Share: Marlboro continued to gain market share (up 0.4pp) to reach a record first-quarter category share of 10.7%.
• Volume Challenge: The overall cigarette category volume share stood at 24.8%, which was a decline of 0.6pp due to an unfavorable mix of markets (specifically citing lower shares in Indonesia, Russia, and Turkey).

🇺🇸 U.S. Business Challenges 🚧

The U.S. segment faced significant headwinds, resulting in lower revenues and adjusted profits compared to the previous year.

• Revenue Decline: Total smoke-free shipment volumes saw a decrease of 21.2%, including a 23.5% drop in ZYN shipments.
• Root Cause: The filings attribute this decline to "distributor and trade inventory movements" in both the current and prior years, as well as comparing against a previously communicated underlying base estimate.
• Focus/Future: Despite the current decline, the company remains committed to the ZYN brand and is actively investing in the U.S. business capabilities. They are preparing for potential future innovations, including ZYN ULTRA, which is currently under active FDA review as part of the nicotine pouch pilot program.

🔮 Forward-Looking Guidance for 2026 🎯

PMI provided comprehensive guidance for the full year of 2026, signaling confidence despite the current market volatility.

• Forecasted EPS: The adjusted diluted EPS is projected to be in a range of $7.56 to $7.71.
• Adjusted Performance: When adjusting for various non-cash items (like intangibles and restructuring), the adjusted diluted EPS is expected to increase by 7.5% to 9.5% versus the 2025 figure.
• Q2 Outlook: Management is projecting the Q2 2026 adjusted diluted EPS to be between $2.02 and $2.07 (this range includes an estimated favorable currency impact).
• Key Assumptions & Strategy: PMI anticipates an estimated industry volume decline of around 2% for cigarettes and HTUs (excluding China and the U.S.).
  • They project net revenue growth of 5% to 7% on an organic basis.
  • The company plans to deploy $1.4 to $1.6 billion in capital expenditures, predominantly supporting the growth of the smoke-free business.
  • The financial goal is to improve the net debt to adjusted EBITDA ratio, aiming for a level close to 2.0x by the end of 2026.

📄 Regulatory Milestones & Long-Term Ambitions 🔬

Beyond the financial numbers, the filing highlighted crucial long-term strategic achievements and regulatory steps, reinforcing PMI's role as a science-backed pioneer in the smoke-free category.

• FDA Authorization: PMI achieved several historic regulatory milestones, including the first-ever FDA authorizations for General snus and ZYN nicotine pouches, and for versions of PMI’s IQOS devices and consumables.
• Risk Mitigation: These new authorizations for Modified Risk Tobacco Products provide a robust foundation for the company’s legal and operational framework in the U.S. market.
• Executive Strategy: Group CEO Jacek Olczak summarized the group's momentum, stating: "Building on excellent broad-based momentum in the international smoke-free business and 16% adjusted diluted EPS growth in Q1, we are well positioned to continue delivering best-in-class performance in 2026." This quote reinforces the focus and confidence in the smoke-free pipeline.

📞 Contact Information and Investor Relations 🧭

If investors or press need more information, the filing provides specific contact channels and the scheduled timing for follow-up conversations.

• Conference Call: A conference call hosted by Group CFO Emmanuel Babeau will be webcast on April 22, 2026, at 9:00 a.m. Eastern Time.
• Investor Relations (Media):
  • Email: [email protected] or [email protected]
  • Stamford, CT Phone: +1 (203) 905 2413
  • Stamford, CT Phone: +1 (203) 905 2410
  • Lausanne Phone: +41 582 424 500

---

🧠 The Analogy

Think of PMI like a giant car manufacturer that realizes the internal combustion engine (combustibles/cigarettes) is becoming outdated. They are systematically pulling most of their profits and resources into developing entirely new electric vehicles (the smoke-free portfolio, especially IQOS and ZYN). The current quarter's results show that while the old engine still provides reliable, profitable income, the new electric vehicles are growing incredibly fast and represent the company's true future value.

🧩 Final Takeaway

PMI's success story is defined by the massive, aggressive shift toward smoke-free products, with IQOS and VEEV acting as primary growth engines. Although the U.S. market and traditional combustibles faced short-term volume challenges, the company has strong management confidence, evidenced by its positive 2026 guidance, tying its future valuation directly to the smoke-free transition.